# ANANDRATHI

4 March 2022

# KSB

## Mixed-bag performance, attractive valuations; retaining a Buy

We believe KSB is well placed to benefit from strong opportunities in FGD, nuclear power, O&G and exports. Such prospects would also boost its after-market and services (15% of its sales) due to increased installed base and expansion in dealer network and service centres. Q4CY21 results were a mixed bag with revenue ahead of estimates due to strong execution. However, increased raw material cost impacted the profitability. CY21 order inflows were of Rs15bn (Rs13bn in CY20) and the management targets Rs25bn order intake in CY24. The favourable demand environment, execution abilities and attractive valuations keep us upbeat. However, due to raw material volatility, we have tweaked our estimates, arriving at a target price of Rs1,352, 25x CY23e P/E. We retain a Buy.

**Performance, a mixed bag.** Q4 revenue grew 20% y/y to Rs4.4bn. Pump revenue was up 25% y/y, while valve revenue slipped 1.6% y/y. Higher raw material prices cut into profitability, with the EBITDA margin contracting 767bps y/y to 12.7% (ARe: 14.6%). Cost controls enabled lower y/y other expenses (as % of sales). Healthy demand and a better CY21 leads us to slightly raise our revenue estimates. On inflation squeezing profitability, we lower our CY22e/CY23e EBITDA by 8.5%/8.4%.

**Good prospects in FGD, nuclear, services.** With capacity built up ahead of competition and pre-qualification in place, we expect good opportunities in FGD and nuclear. NPCIL announced 12 reactors (each of 700MW), a Rs5bn opportunity each, by 2031. FGD and the Atma Nirbhar vision are perceived as large opportunities. The company is eyeing increased services (25-30% revenue targeted) and export business in coming years. Agriculture, "smart" cities, wastewater management and O&G also throw up healthy prospects.

**Valuations:** With tweaks to our estimates, we expect 13%/12% revenue/PAT CAGRs over CY21-23e. The stock trades at an attractive 23x/20x CY22e/CY23e P/E. We maintain our Buy rating with a lower target price of Rs1,352 (earlier Rs1,494), 25x CY23e P/E. **Risk**: Lower-than-expected order awarding.

| Key financials (YE Dec)          | CY19   | CY20   | CY21   | CY22e  | CY23e  |
|----------------------------------|--------|--------|--------|--------|--------|
| Sales (Rs m)                     | 12,939 | 12,081 | 14,973 | 16,355 | 19,199 |
| Net profit (Rs m)                | 918    | 938    | 1,494  | 1,577  | 1,882  |
| EPS (Rs)                         | 26.4   | 27.0   | 42.9   | 45.3   | 54.1   |
| PE (x)                           | 40.0   | 39.1   | 24.6   | 23.3   | 19.5   |
| EV / EBITDA (x)                  | 22.7   | 19.8   | 15.8   | 14.8   | 12.2   |
| PBV (x)                          | 4.4    | 4.1    | 3.6    | 3.2    | 2.9    |
| RoE (%)                          | 11.6   | 10.9   | 15.7   | 14.7   | 15.7   |
| RoCE (%)                         | 14.4   | 16.1   | 19.4   | 18.7   | 20.1   |
| Dividend yield (%)               | 0.8    | 0.8    | 0.8    | 0.9    | 1.0    |
| Net debt / equity (x)            | -0.3   | -0.4   | -0.4   | -0.4   | -0.4   |
| Source: Company, Anand Rathi Res | search |        |        |        |        |

Rating: **Buy** Target Price: Rs.1,352 Share Price: Rs.1,055

| k      | (SB IN / K                            | SBP.BO  |
|--------|---------------------------------------|---|
|        | Rs.14                                 | 11/738  |
|        | 55103                                 | / 16498   |
|        |                                       | \$0.5m  |
| Rs     | .37bn / \$                            | 483.8m  |
|        |                                       | 35m   |
|        |                                       |   |
| Dec'21 | Sep'21                                | Jun'21  |
| 66.7   | 66.7                                  | 66.7  |
| -      | -                                     | -   |
| 33.3   | 33.3                                  | 33.3  |
| 2.9    | 2.8                                   | 2.6   |
| 11.1   | 11.6                                  | 11.6  |
| 19.3   | 18.9                                  | 19.2  |
|        |                                       |   |
|        | CY22                                  | CY23  |
|        | 2.2                                   | 2.9   |
|        | -8.5                                  | -8.4  |
|        | -9.7                                  | -9.6  |
|        | Dec'21<br>66.7<br>33.3<br>2.9<br>11.1 | 55103   Rs.Jrbn / \$   Dec'21 Sep21   66.7 66.7   33.3 33.3   2.9 2.8   11.1 11.6   19.3 18.9   CY22   2.2 -8.5 |



Source: Bloomberg

Ashwani Sharma Research Analyst

> Rahul Jain Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

India I Equities

Industrial Consumables Company Update Change in Estimates ☑ Target ☑ Reco □

# **Quick Glance - Financials and Valuations**

| Fig 1 – Income stateme      | ent (Rs n | ו)     |             |        |        |
|-----------------------------|-----------|--------|-------------|--------|--------|
| Year-end: Dec               | CY19      | CY20   | CY21        | CY22e  | CY23e  |
|                             |           |        |             |        |        |
| Net revenues (Rs m)         | 12,939    | 12,081 | 14,973      | 16,355 | 19,199 |
| Growth (%)                  | 18.4      | -6.6   | 23.9        | 9.2    | 17.4   |
| Material cost               | 6,983     | 6,206  | 7,924       | 8,636  | 10,137 |
| Employee & Other expense    | 4,438     | 4,197  | 4,955       | 5,515  | 6,455  |
| EBITDA                      | 1,518     | 1,678  | 2,094       | 2,205  | 2,607  |
| EBITDA margins (%)          | 11.7      | 13.9   | 14.0        | 13.5   | 13.6   |
| Depreciation                | 457       | 418    | 435         | 441    | 484    |
| Other income                | 216       | 291    | 337         | 339    | 395    |
| Interest expenses           | 53        | 34     | 50          | 34     | 36     |
| PBT                         | 1,224     | 1,517  | 1,946       | 2,069  | 2,482  |
| Effective tax rate (%)      | 29.5      | 41.7   | 26.5        | 27.0   | 27.0   |
| + Associates / (Minorities) | 54        | 53     | 64          | 67     | 71     |
| Net income                  | 1,007     | 938    | 1,494       | 1,577  | 1,882  |
| Adjusted income             | 918       | 938    | 1,494       | 1,577  | 1,882  |
| WANS                        | 35        | 35     | 35          | 35     | 35     |
| FDEPS (Rs / sh)             | 26.4      | 27.0   | 42.9        | 45.3   | 54.1   |
| EPS growth (%)              | 28.1      | 2.2    | <i>59.3</i> | 5.6    | 19.3   |


#### Fig 3 – Cash-flow statement (Rs m)


| 5                               | •       |       |       |       |       |
|---------------------------------|---------|-------|-------|-------|-------|
| Year-end: Dec                   | CY19    | CY20  | CY21  | CY22e | CY23e |
| PBT                             | 1,351   | 1,517 | 1,946 | 2,069 | 2,482 |
| + Non-cash items                | 294     | 161   | 148   | 136   | 125   |
| Oper. prof. before WC           | 1,645   | 1,678 | 2,094 | 2,205 | 2,607 |
| - Incr. / (decr.) in WC         | 688     | 341   | -678  | -509  | -280  |
| Others incl. taxes              | -348    | -625  | -558  | -559  | -670  |
| Operating cash-flow             | 1,985   | 1,394 | 858   | 1,137 | 1,657 |
| - Capex (tang. + intang.)       | -626    | -452  | -497  | -577  | -880  |
| Free cash-flow                  | 1,360   | 942   | 361   | 560   | 777   |
| Acquisitions                    | -       | -     | -     | -     | -     |
| - Div. (incl. buyback & taxes)  | 323     | 296   | 296   | 312   | 373   |
| + Equity raised                 | 26      | -24   | 4     | -67   | -71   |
| + Debt raised                   | 166     | -     | -600  | -     | -     |
| - Fin investments               | 46      | 18    | 35    | 10    | 20    |
| - Misc. (CFI + CFF)             | -332    | -529  | -78   | -352  | -430  |
| Net cash-flow                   | 1,514   | 1,133 | -488  | 522   | 743   |
| Source: Company, Anand Rathi Re | esearch |       |       |       |       |
|                                 |         |       |       |       |       |

#### Fig 2 – Balance sheet (Rs m) Year-end: Dec CY19 CY20 CY21 CY22e CY23e Share capital 348 348 348 348 348 Net worth 8,288 8,906 10,108 11,306 12,745 Debt 600 600 Minority interest DTL / (Assets) -16 -9 -51 -51 -51 9,497 10,057 Capital employed 8,872 11,255 12,694 Net tangible assets 3,057 3,171 3,093 3,330 3,725 Net intangible assets 13 13 14 13 Goodwill CWIP (tang. & intang.) 345 392 292 292 251 Investments (strategic) -Investments (financial) 697 707 727 644 662 Current asset (excl cash) 7,396 11,331 7,261 8,302 9,867 Cash 4,068 2,901 4,034 3,546 4,811 Current liabilities 7,022 8,205 5,471 5,896 5,986 Working capital 2,845 3,125 1,925 1,365 2,316 10,057 Capital deployed 8,872 9,497 11,255 12,694 Contingent liabilities

#### Fig 4 – Ratio analysis

| Year-end: Dec                      | CY19  | CY20  | CY21 | CY22e | CY23e |
|------------------------------------|-------|-------|------|-------|-------|
| P/E (x)                            | 40.0  | 39.1  | 24.6 | 23.3  | 19.5  |
| EV / EBITDA (x)                    | 22.7  | 19.8  | 15.8 | 14.8  | 12.2  |
| EV / Sales (x)                     | 2.7   | 2.8   | 2.2  | 2.0   | 1.7   |
| P/B (x)                            | 4.4   | 4.1   | 3.6  | 3.2   | 2.9   |
| RoE (%)                            | 11.6  | 10.9  | 15.7 | 14.7  | 15.7  |
| RoCE (%) - after tax               | 14.4  | 16.1  | 19.4 | 18.7  | 20.1  |
| RoIC (%) - after tax               | 14.8  | 16.4  | 25.1 | 22.8  | 24.9  |
| DPS (Rs / sh)                      | 8.0   | 8.5   | 8.5  | 9.0   | 10.7  |
| Dividend yield (%)                 | 0.8   | 0.8   | 0.8  | 0.9   | 1.0   |
| Dividend payout (%) - incl. DDT    | 32.1  | 31.5  | 19.8 | 19.8  | 19.8  |
| Net debt / equity (x)              | -0.3  | -0.4  | -0.4 | -0.4  | -0.4  |
| Receivables (days)                 | 84    | 86    | 71   | 85    | 84    |
| Inventory (days)                   | 92    | 109   | 103  | 110   | 110   |
| Payables (days)                    | 77    | 92    | 79   | 93    | 94    |
| CFO: PAT %                         | 216.4 | 148.6 | 57.4 | 72.1  | 88.0  |
| Source: Company, Anand Rathi Resea | rch   |       |      |       |       |





## Fig 5 - Price movement



# Result Highlights

| Fig 7 – Quarterly and a | innual trends |         |         |         |         |        |        |         |
|-------------------------|---------------|---------|---------|---------|---------|--------|--------|---------|
| (Rs m)                  | Q4 CY21       | Q4 CY20 | Y/Y (%) | Q3 CY21 | Q/Q (%) | CY21   | CY20   | Y/Y (%) |
| Net revenue             | 4,446         | 3,699   | 20.2    | 3,681   | 20.8    | 14,973 | 12,081 | 23.9    |
| EBITDA                  | 564           | 753     | (25.1)  | 517     | 9.1     | 2,094  | 1,678  | 24.8    |
| EBITDA margins (%)      | 12.7          | 20.4    | -767bps | 14.0    | -136bps | 14.0   | 13.9   | 10bps   |
| Other income            | 82            | 28      | 192.9   | 99      | (17.2)  | 337    | 291    | 15.8    |
| Depreciation            | 110           | 117     | (6.0)   | 109     | 0.9     | 435    | 418    | 4.1     |
| Interest                | 19            | 7       | 171.4   | 12      | 58.3    | 50     | 34     | 47.1    |
| Share of JV / Assoc.    | 20            | 24      | (16.7)  | 13      | 53.8    | 64     | 53     | 20.8    |
| Profit before tax       | -             | -       |         | -       |         | -      | -      |         |
| Тах                     | 537           | 681     | (21.1)  | 508     | 6       | 2,010  | 1,570  | 28.0    |
| PAT                     | 143           | 361     | (60.4)  | 119     | 20.2    | 516    | 632    | (18.4)  |
| Net margins (%)         | 394           | 320     | 23.1    | 389     | 1.3     | 1,494  | 938    | 59.3    |
| Source: Company         |               |         |         |         |         |        |        |         |

| Fig 8 – Cost anal  | ysis    |         |         |         |         |         |         |         |         |         |         |         |
|--------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| (Rs m)             | Q1 CY19 | Q2 CY19 | Q3 CY19 | Q4 CY19 | Q1 CY20 | Q2 CY20 | Q3 CY20 | Q4 CY20 | Q1 CY21 | Q2 CY21 | Q3 CY21 | Q4 CY21 |
| Sales              | 2893    | 3018    | 3658    | 3370    | 2570    | 2189    | 3623    | 3699    | 3816    | 3030    | 3681    | 4446    |
| Raw material costs | 1552    | 1608    | 2082    | 1741    | 1308    | 1253    | 1942    | 1703    | 1891    | 1569    | 1969    | 2495    |
| Employee costs     | 417     | 455     | 439     | 468     | 475     | 450     | 477     | 460     | 520     | 503     | 534     | 597     |
| Other expenses     | 606     | 634     | 750     | 684     | 607     | 350     | 595     | 783     | 785     | 565     | 661     | 790     |
| % of sales         |         |         |         |         |         |         |         |         |         |         | -       |         |
| Raw material costs | 53.6    | 53.3    | 56.9    | 51.7    | 50.9    | 57.2    | 53.6    | 46.0    | 49.6    | 51.8    | 53.5    | 56.1    |
| Employee costs     | 14.4    | 15.1    | 12.0    | 13.9    | 18.5    | 20.6    | 13.2    | 12.4    | 13.6    | 16.6    | 14.5    | 13.4    |
| Other expenses     | 20.9    | 21.0    | 20.5    | 20.3    | 23.6    | 16.0    | 16.4    | 21.2    | 20.6    | 18.6    | 18.0    | 17.8    |
| EBIDTA margins     | 11.0    | 10.6    | 10.6    | 14.2    | 7.0     | 6.2     | 16.8    | 20.4    | 16.2    | 13.0    | 14.0    | 12.7    |
| Source: Company    |         |         |         |         |         |         |         |         |         |         |         |         |

# **Conference-call highlights**

KSB's management commentary was largely around

1) Increasing service (from 15% in CY21 to 25-30% in the next five years) led by greater installed base and the exports business.

2) Strengthening its product basket and dealer network,

3) Focus on cost controls through various measures like digitisation and solar power, and

4) Delays in the nuclear power project.

For CY24, it aims at orders of Rs25bn, sales of Rs22bn and a 13% EBITDA margin.

#### Standard pumps

Revenue from standard pumps climbed to 48% in CY21, from CY20's 41%, driven primarily by the higher projects business seeing greater demand from agriculture, industry, water and waste water and buildings. The upgrading of its pumps and greater localisation is intensifying competitiveness in the Indian market.

The higher revenue was also supported by the strengthened sales team and focus on expanding the dealer network (adding 100 dealers yearly). The company intends to maintain the contribution for the coming years. Besides, it launched gamma pumps and seeks to cater to the pulp-paper industry from where demand is increasing. 60-70% of its business comes from its current dealer/ distributor network, the rest from OEMs, direct sales and smaller projects.

## FGD

In FGD, the company bagged orders of Rs295m, from NTPC, DVC Mejia and NTPL. In CY21, it supplied 170 pumps. Apart from robust demand, the company also eyes significant spares and service business for the rotating parts that will be replaced in the next 2-3 years. It expects good spares and service revenue in FGD from FY24, driven by larger installed base.

#### Nuclear Power

NPCIL bulk tender of Rs15bn, consisting of 24 pumps and 30 motors, at three sites with two units each and four pumps per unit. Details of the first site of Rs5bn should be finalized by Mar/Apr'22; the other two sites will be re-tendered, expected to be finalized by end-CY22 or early CY23. The tendering process for the last 16 pumps might extend up to CY24 or beyond. We believe the long-term opportunity in nuclear power (ie, from NPCIL) is robust. KSB will be among the biggest beneficiaries due to its localization.

#### Gamma pumps

In CY21 KSB developed gamma pumps, used in industry and water and waste water treatment. It already has orders for  $\sim$ 340 pumps and looks at 500-600 pump orders in CY22. The market is  $\sim$ 10,000-15,000 pumps a year. In the next 2-3 years, the company looks at annual sales of 1,500-2,000 pumps. In CY21, Rs10m revenue came from selling 325 gamma pumps. Also, it received the IP from its parent for gamma pumps as an exception, as the market is very vast.

# Focus on rising exports, services & spares

#### **Exports**

Export revenue in CY21 shot up 44% y/y to Rs2.9bn; its proportion to revenue rose from 17.1% in CY20 to 20.2% in CY21. Its exports constitute direct sales (30%) and orders through its parent (70%). Most of its exports are through its parent except for its business in Nepal and Bangladesh. New products such as gamma and solar pumps provide vast opportunities for the group's business internationally.

## **Spares and Services**

Revenue of the spares & services business (SupremeServ) in CY21 grew 12% y/y to Rs1.7bn; its proportion to total revenue was unchanged at 15%. The company intends to increase this to 25-30% in the next five years, enabled by a wider distribution and service network, aiming to deliver spare parts (standard products) in 48 hours. The company has 200+ authorized service centres across India. These provide services concerning standard products (like submersible, industrial and other standard pumps) in various regions and buy spares from KSB. Hence, the focus will be on improving connectivity for faster deliveries of spares.

For engineered products, the company conducts business directly. It has onground engineering and service teams who provide services and spares. It is also targeting companies to service old pumps installed by the competition, mainly international pump manufacturers. Besides, it has opened a new service station in Baddi, HP, helping it serve customers in the northern region.

## Strong order intake in CY21

Despite the pandemic, orders were a strong Rs15bn in CY21, vs Rs13.3bn in CY20. In Q4 CY21m the company secured orders of Rs295m for 22 pumps in FGD from NTPC, DVC Mejia and NTPL. It is also seeing good success in solar pumps. It bagged domestic and export orders of Rs82.7m for 328 gamma pumps in CY21. Management is seeing greater traction from O&G with numerous enquiries and projects in the pipeline. The business, however, has been volatile. KSB has done good business in CY19, but did not have much inflows in CY21. It has bagged good orders in the first two months of CY22. For O&G, it is in the process of developing various products.

#### Price hikes

Against the 20-25% rise in raw material prices, the company hike prices 12-15%. Management expects margins to be under pressure as cost benefits due to Covid-19 will be non-existent as travel has re-started. Besides, higher raw material prices and supply-chain disruptions continue to bite. It is mitigating this risk by reducing power costs through installing solar power, digitising processes and eyeing more business from services (a high-margin segment).


## Other key highlights

- The top-10 customers accounted for 26.3% of domestic revenue.
- For agriculture, the company is seeking to increase product efficiency and quality, gaining a higher rating for its pumps i.e. 4- and 5-Star. This will lead to greater acceptability in this segment.


| Fig 9 – Top-ten customers      | S                                    |              |                               |
|--------------------------------|--------------------------------------|--------------|-------------------------------|
| Customer                       | Segment                              | Value (Rs m) | % of domestic<br>Order inflow |
| Bharat Heavy Electricals.      | Energy                               | 1,045        | 7.9                           |
| The Thermax Group              | Energy                               | 425          | 3.2                           |
| Rushabh Enterprises            | General industry                     | 322          | 2.4                           |
| ISGEC Heavy Engineering.       | Energy                               | 311          | 2.3                           |
| Patil Engineering              | General industry                     | 304          | 2.3                           |
| RK Engineers Sales.            | Water                                | 265          | 2.0                           |
| Larsen & Toubro                | Energy, buildings,<br>petrochemicals | 253          | 1.9                           |
| Pooja Engineering Co.          | Petro-chemicals, general industry    | 240          | 1.8                           |
| NTPC                           | Energy                               | 169          | 1.3                           |
| Thyssenkrupp Industries, India | Energy, petro-chemicals              | 160          | 1.2                           |
| Total                          |                                      | 3494         | 26.3                          |
| Source: Company                |                                      |              |                               |


# Fig 10 – Status, major investments of 2022

| Investments                             | Amount (Rs m) | Remarks  |
|---|---------------|--|
|   |               | The Sinnar shed is nearing completion.   |
| Sinnar shed                             | 232           | Small items like compressors, etc. of €0.11m will be installed in CY22           |
|   |               | SAP warehouse management project implementation stared                           |
| Digitization - RPA and various projects | 32            | Mobile warehouse management digitisation in 2022. RPA -Pilot phase completed.    |
| Gamma development project               | 9             | Completed  |
| Central spares warehouse expansion      | 9             | Completed  |
| Ground floor office renovation - CBE    | 34            | Admin office completed, production office renovation is ongoing                  |
| Patterns – In-house and Sub-contract    | 57            | Various patterns including in-house and sub-contract                             |
|   |               | ITS hardware and software: Rs24m, vehicles: Rs3m, Baddi service station: Rs2.8m, |
| Other regular investments               | 182           | evaporative cooling system Sinnar: Rs7m, Etabloc pump casing development: Rs2.8m |
| Total investments                       | 531           |  |
| Source: Company                         |               |  |



|                           | CY19 | CY20 | CY21 |
|---------------------------|------|------|------|
| Agriculture               | 13   | 14   | 15   |
| Solar                     | 0.2  | 0.2  | 0.7  |
| Buildings                 | 10   | 10   | 12   |
| Water and Waste water     | 1    | 2    | 2    |
| Standard industry         | 16   | 17   | 20   |
| Standard products         | 40   | 43   | 48   |
| Petro-chemicals           | 16   | 10   | 7    |
| Energy + Special projects | 16   | 15   | 16   |
| Engineered products       | 31   | 25   | 23   |
| SupremeServ               | 13   | 16   | 12   |
| Valves                    | 15   | 15   | 16   |
| Total                     | 100  | 100  | 100  |
| Source: Company           |      |      |      |





Source: Company


# Valuation

Expectations of a pick-up in awarding orders, its strong parent backing and execution ability augur well for the company. We expect 13%/12% growth in revenue/PAT over CY21-23. 13.5%/13.6% EBITDA margins are expected in CY22/CY23.

The stock trades at an attractive 23x/20x CY23e earnings. Strong operations, execution capabilities and attractive valuations enable us to remain upbeat on it. Valuing it at 25x CY23e earnings, we arrive at a revised target price of Rs1,352 (earlier Rs1,494). We retain a Buy.

| Fig 14 – Chai | nge in estimate | es     |        |        |          |      |
|---------------|-----------------|--------|--------|--------|----------|------|
|               | Old             |        | New    |        | % Change |      |
| (Rs m)        | CY22e           | CY23e  | CY22e  | CY23e  | CY22     | CY23 |
| Sales         | 16,003          | 18,654 | 16,355 | 19,199 | 2.2      | 2.9  |
| EBITDA        | 2,411           | 2,846  | 2,205  | 2,607  | -8.5     | -8.4 |
| EPS (Rs)      | 50.2            | 59.8   | 45.3   | 54.1   | -9.7     | -9.6 |





Source: Bloomberg

#### Key risk


- Delay in booking orders caused by postponements by the NPCIL.
- Deferred capex on higher-than-anticipated costs due to the rise in commodity prices.
- Competition can eat into its market share in agricultural and residential pumps.
- Unable to pass on increases in commodity prices.

#### Appendix

#### Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

#### Important Disclosures on subject companies Rating and Target Price History (as of 4 March 2022)



#### Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

| Ratings Guide (12 months)   |      |       |      |
|---|------|-------|------|
| <b>.</b>  | Buy  | Hold  | Sell |
| Large Caps (>US\$1bn)   | >15% | 5-15% | <5%  |
| Mid/Small Caps ( <us\$1bn)< th=""><th>&gt;25%</th><th>5-25%</th><th>&lt;5%</th></us\$1bn)<> | >25% | 5-25% | <5%  |

#### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

#### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

| Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.   | No |
|---|----|
| ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report? | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company  | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months  | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months  | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months        | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.   | No |

#### Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.

2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.

3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.

4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.

5. As of the publication of this report, ARSSBL does not make a market in the subject securities.

6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2021. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097. Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.